Tetrazole

Tetrazole

SCHEMBL4710754

FC(F)(F)c1cccc(COc2ccc(-c3cnc4c(-c5nnn[nH]5)cnn4c3C3CCCCC3)cc2)c1.c1nnn[nH]1

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
PDGFRA P16234 1/20 0.36
S1PR1 P21453 1/20 0.36
S1PR5 Q9H228 1/20 0.36
AXL P30530 1/20 0.35
TYRO3 Q06418 1/20 0.35
MERTK Q12866 1/20 0.35
MAOB P27338 6/20 0.35
GPR119 Q8TDV5 4/20 0.35
ALOX5AP P20292 2/20 0.34
FEN1 P39748 1/20 0.34
MAP4K3 Q8IVH8 1/20 0.34
NR4A2 P43354 1/20 0.33
MMP1 P03956 1/20 0.33
ADAM17 P78536 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
XBP1 P17861 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4710343 0.95 CYP3A4 (0.39) CYP3A4CYP2D6PDGFRAS1PR1S1PR5
SCHEMBL14014561 0.89 PLAT (0.39) CYP3A4CYP2D6PDGFRAS1PR1S1PR5
SCHEMBL14014616 0.86 JAK1 (0.40) MAOBGPR119ALOX5APFEN1ADAM17
SCHEMBL14014625 0.86 GPR119 (0.37) AXLTYRO3MERTKGPR119ALOX5AP
SCHEMBL14542125 0.84 CYP4F2 (0.35) MAOB
SCHEMBL14014679 0.84 ALOX5 (0.37) MAOBGPR119LMNAPOLB
SCHEMBL14014558 0.84 TNK2 (0.41) PDGFRAAXLTYRO3MERTKGPR119
SCHEMBL14014615 0.83 MAOB (0.37) MAOBMAP4K3LMNA
SCHEMBL14014628 0.83 PDE2A (0.33) S1PR1S1PR5GPR119ALOX5AP
SCHEMBL14014630 0.83 GPR119 (0.34) AXLTYRO3GPR119ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449488-B2 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2008-11-11 US disclosed
EP-1511751-B1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS NEOGENESIS PHARMACEUTICALS INC (US) 2008-03-19 EP disclosed
US-7196111-B2 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents SCHERING CORPORATION (US) 2007-03-27 US disclosed
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors SCHERING CORPORATION 2006-05-04 US disclosed
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents NEOGENESIS PHARMACEUTICALS, INC. 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038993-A1 Pyrazolo[1,5a]pyrimidine compounds as antiviral agents RNGTT, PNP, ZC3HAV1 CYP3A4 636/4885CYP2D6 936/4885PDGFRA 1110/4885
US-20060094706-A1 Pyrazolopyrimidines as protein kinase inhibitors CDKN1A, EIF2AK2, DCK CYP3A4 3113/4885CYP2D6 3132/4885PDGFRA 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.